The reiteration of an Overweight rating and maintenance of a $25 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Catalyst Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential growth and performance.